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Background
IgA plays a protective role at mucosal surfaces by facilitat-
ing the binding of IgA-coated targets to Fc receptors
(FcαR) on effector cells. Human monocytes, macro-
phages, neutrophils and some dendritic cells express cell
surface FcαR that mediates effector functions such as
phagocytosis, Ab-dependent cell cytotoxicity and inflam-
matory mediator release. Moreover, we recently demon-
strated that certain IgG Fc receptors expressed on TZM-bl
cells augment the neutralizing activity of gp41 MPER-spe-
cific Abs.
Methods
To gain insight in the role of CD89 in HIV infectivity and
neutralization, the cDNAs for the human FcαRI and the
FcRγ chain were transduced into TZM-bl cells.
Results
Stable surface expression of FcαRI and the FcRγ chain on
this new TZM-bl cell line was confirmed by flow cytome-
try. In addition, the FcαR expressed on this cell line was
able to bind secretory IgA from human colostrum. The cell
line was fully susceptible to HIV-1 infection as the levels
of CD4, CCR5, and CXCR4 remained comparable to the
parental cell line. In contrast to what we have observed
with FcγRs expression on TZM-bl cells, FcαR expression
had no effect on the neutralizing activity of an IgA version
of 2F5 when assayed against four different HIV-1 variants.
Conclusion
Our preliminary results suggest that FcαR has no effect on
the neutralizing activity of gp41 MPER-specific IgA. Thus,
the phenomenon observed with FcγRs and MPER anti-
bodies seems to be immunoglobulin class and Fc receptor
specific. Additional work is in progress to characterize
other HIV-1-specific IgAs.
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